EGFR-Mutated Stage IV Lung Adenocarcinoma With Painful Finger Lesions During Osimertinib

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: EGFR-mutated; EGFR T790M-positive at relapse

She remained on active osimertinib treatment; the finger lesions persisted but were controlled with colloidal oatmeal.

PubMed CentralRead more →

Lung Adenocarcinoma Diagnosed After a Bronchoscopy Complication

Patient Info: Anonymized, Male, 60s

He remained under active oncology follow-up after chemotherapy and radical radiotherapy.

PubMed CentralRead more →

Lung Cancer: David's Survivor Story

Patient Info: David Sherman, Male, 70+

All cancerous tissue was removed. David reported no pain or breathing difficulty after surgery, and doctors estimated a 90% 5-year survival chance.

Cleveland ClinicRead more →

Lung cancer presenting with brain and leptomeningeal spread

Patient Info: Anonymized, Male, 70+ | Stage IV

Biomarkers: PD-L1 100%; EGFR negative; ALK rearrangement negative

Metastatic Site: brain, leptomeninges

His condition deteriorated within weeks of radiotherapy. He was readmitted with pneumonia and an acute right frontal brain haemorrhage and died within 1 week; metastatic lung adenocarcinoma was recorded as the cause of death.

PubMed CentralRead more →

Small cell lung cancer presenting with spontaneous tumor lysis syndrome

Patient Info: Anonymized, Male | Stage IV

Metastatic Site: liver

He developed rapidly worsening encephalopathy, gastrointestinal bleeding, cyanosis and mottling and died before planned chemotherapy could be started.

PubMed CentralRead more →

Stage IV EGFR Lung Cancer: Molly's Patient Story

Patient Info: Molly Golbon, Female, Under 40 | Stage IV

Biomarkers: EGFR mutation

Metastatic Site: Left hip; right shoulder; brain

Molly had a strong early response to Tarceva for Stage IV EGFR-mutated lung cancer, with about 50% tumor shrinkage after 2 months and metastatic disease described as almost undetectable; no later remission/NED status is provided in this record.

The Patient StoryRead more →

Autoimmune hemolytic anemia after 39 cycles of nivolumab for metastatic lung cancer

Patient Info: Anonymized, Male, 70+ | Stage IV

Metastatic Site: liver, bone

While nivolumab remained on hold, his lung cancer was stable on imaging and clinically, and hemoglobin had recovered to 14.6 g/dL about 4 months after high-dose prednisone and rituximab began.

PubMed CentralRead more →

Metastatic lung cancer causing recurrent small-bowel intussusception

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: EGFR mutation; exon 19 deletion in metastatic bowel lesions

Metastatic Site: small bowel

She recovered satisfactorily after bowel surgery, and care shifted to palliation with long-term nutritional support planned.

PubMed CentralRead more →

Metastatic lung adenocarcinoma causing sudden hearing loss and vertigo

Patient Info: Anonymized, Female, 60s | Stage IV

Metastatic Site: bone|liver|brain|internal auditory meatus

About 10 months after the metastatic diagnosis, she developed new left-sided deafness, vertigo and facial weakness associated with metastatic involvement of the internal auditory meatus.

PubMed CentralRead more →

Typical lung carcinoid near the main airway treated with staged procedures and surgery

Patient Info: Anonymized, Male, Under 40

Biomarkers: Ki-67 2%; synaptophysin positive; chromogranin positive

After definitive surgery, the resection margins were clear and no postoperative chemotherapy or radiotherapy was recommended. He remained asymptomatic with surveillance CT and DOTATATE PET imaging planned.

PubMed CentralRead more →

Stage IV Squamous Lung Cancer Resected After Response to Checkpoint Immunotherapy

Patient Info: Anonymized, male, 50s | Stage IV

After complete resection, he was alive, disease free and off treatment at postoperative follow-up.

PubMed CentralRead more →

Stage III Lung Adenocarcinoma Resected After Chemotherapy and Checkpoint Immunotherapy

Patient Info: Anonymized, female, 60s | Stage III

After complete resection, she was alive, disease free and off treatment at postoperative follow-up.

PubMed CentralRead more →

Metastatic Large Cell Neuroendocrine Lung Cancer With No Residual Tumor After Immunotherapy and Surgery

Patient Info: Anonymized, male, 50s

Surgical pathology showed fibrosis with no residual cancer, and he remained alive, disease free and off treatment at postoperative follow-up.

PubMed CentralRead more →

Oligometastatic Lung Cancer With Brain Spread, Surgery and Later Recurrence

Patient Info: Anonymized, male, 60s | Stage IV

Metastatic Site: brain

After 15 months off treatment he developed mediastinal nodal and distant metastases and was alive with disease on platinum-based chemotherapy 25 months after surgery.

PubMed CentralRead more →

Metastatic Lung Cancer With Adrenal Spread and No Residual Tumor After Immunotherapy and Surgery

Patient Info: Anonymized, female, 50s

Final lung pathology showed no residual viable cancer, and she remained alive, disease free and off treatment at postoperative follow-up.

PubMed CentralRead more →

Small cell lung cancer found after severe digestive and neurologic symptoms

Patient Info: Anonymized, Male, 50s

Biomarkers: ANNA-1 positive at 1:61, 440; neuronal acetylcholine receptor antibody 0.05 nmol/L

His speech and strength improved with treatment, and PET/CT 4 months after the initial assessment showed no recurrent or metastatic lung cancer.

PubMed CentralRead more →

Small Cell Lung Cancer Presenting With a Nasal Cavity Metastasis

Patient Info: Anonymized, male, 50s

Biomarkers: CD56 positive, chromogranin positive, synaptophysin positive

After 12 months in remission, the nasal cavity disease recurred aggressively. He declined further palliative chemotherapy and died 2 months later, 14 months after diagnosis.

PubMed CentralRead more →

A Lung Carcinoid Found During Evaluation of Severe Diarrhea

Patient Info: Anonymized, male, 50s

Biomarkers: neuron-specific enolase negative, chromogranin A negative

At 6-month follow-up, CT showed only previously noted emphysema, neuroendocrine tumor markers were negative, and he remained asymptomatic.

PubMed CentralRead more →

Finding Happiness Despite Stage IV Lung Cancer

Patient Info: Anonymized, 50s | Stage IV

More than a year after diagnosis, she remained in treatment for Stage IV lung cancer, with some therapies losing effectiveness as the cancer developed resistance.

Dana-FarberRead more →

Stage IV ERBB2-Mutated Lung Adenocarcinoma Responding to HER2-Targeted Therapy

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: ERBB2 exon 20 insertion

Metastatic Site: bilateral lungs

Afatinib showed a response after 1 month, but insurance denial required a return to trastuzumab-based treatment.

PubMed CentralRead more →

Stage IV ERBB2-Mutated Lung Cancer With Extensive Bone Metastases

Patient Info: Anonymized, female, 60s | Stage IV

Biomarkers: ERBB2 exon 20 insertion. A PIK3CA mutation was later detected at progression and considered a possible resistance mechanism.

Metastatic Site: bone

After progression on pemetrexed following several earlier treatment lines, she transitioned to hospice care.

PubMed CentralRead more →

Stage IV ERBB2-Mutated Lung Adenocarcinoma With Brain Metastases and Multiple Targeted Therapies

Patient Info: Anonymized, female, Under 40 | Stage IV

Biomarkers: ERBB2 exon 20 insertion, exact sequence not specified. ERBB2 copy-number gain was identified during progression on afatinib.

Metastatic Site: brain, adrenal gland, liver

The final documented afatinib plus bevacizumab rechallenge produced a mixed response followed by liver progression after 3 months.

PubMed CentralRead more →

ERBB2-Mutated Metastatic Lung Adenocarcinoma With Leptomeningeal Progression

Patient Info: Anonymized, male

Biomarkers: ERBB2 A775_G776 insYVMA mutation with amplification

The final treatment produced a mixed systemic response, but leptomeningeal disease developed.

PubMed CentralRead more →

ERBB2-Mutated Metastatic Lung Adenocarcinoma With Treatment Intolerance and Progression

Patient Info: Anonymized, male

Biomarkers: ERBB2 A775_G776 insYVMA mutation

After poorly tolerated earlier regimens with stable disease, he developed symptomatic progression during 1 month of afatinib.

PubMed CentralRead more →